Pixuvri’s Conditional EU Approval Could Herald The Rise Of Staggered Approval

CTI’s conditional EU approval for its non-Hodgkin B-cell lymphoma drug Pixuvri goes against the run of the drug in the US, but reinforces the idea that staggered approvals are on the way in Europe.